« Previous
Next »
Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2
, Pages
382-390
, April 2010
Tumor-associated macrophages are predominant carriers of cyclodextrin-based nanoparticles into gliomas
To access this article, please choose from the options below
The senior author owns stocks in Arrowhead Research Inc, which is a part owner of Calando Pharmaceuticals.
This work was supported by American Cancer Society Research Scholar Grant (RSG-03-142-01-CNE), the James S. McConnell Foundation, and Insert Therapeutics (to B. Badie). The City of Hope Flow Cytometry Core was equipped in part through funding provided by ONR N00014-02-1 0958, DOD 1435-04-03GT-73134, and NSF DBI-9970143.
PII: S1549-9634(09)00189-0
doi: 10.1016/j.nano.2009.10.001
© 2010 Elsevier Inc. All rights reserved.
« Previous
Next »
Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 2
, Pages
382-390
, April 2010
